Digital health and biotech investors are being left in the dark about the quality of research emerging from local health sciences companies and academic institutes, according to specialist advisory firm Chrysalis Advisory.

Read the full article by Yolanda Redrup published on The Australian Financial Review and insights from Chrysalis Managing Partner, Nick Northcott to find out more about why biotech investors need a research ombudsman.

Read more: Why biotech investors need a research ombudsman

#research #biotech #researchintegrity